Quantum BioPharma is trading 6.49% down at $3.25, despite broader U.S. markets moving higher on cooler inflation and easing interest-rate concerns; no fresh company-specific catalyst was identified for August 13, 2026.
- FDA clearance for Lucid-MS Phase 2 was announced August 10, not August 13.
- Earnings were listed for August 13, but no results were available.
- The decline remains unexplained and warrants monitoring for delayed company news.